Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals (NASDAQ: JAZZ) presented significant Phase 4 data and real-world evidence for Xywav® at World Sleep 2025 and Psych Congress 2025. The key findings from the DUET trial demonstrated positive treatment effects of low-sodium Xywav on both daytime and nighttime symptoms in adults with narcolepsy or idiopathic hypersomnia (IH).
Notable results include improved sleep measures with fewer awakenings in narcolepsy patients, reduced sleep inertia in IH patients, and positive outcomes for patients taking 9-12 gram doses. Real-world analysis revealed that individuals with narcolepsy or IH have an elevated risk of cardiovascular, cardiometabolic and renal complications, emphasizing the importance of low-sodium treatment options.
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that Modeyso™ (dordaviprone) has been included in the NCCN Clinical Practice Guidelines as a category 2A treatment option for H3 K27M-mutant diffuse glioma. This follows the FDA's accelerated approval on August 6, 2025 for treating adult and pediatric patients with diffuse midline glioma.
Clinical trials demonstrated an overall response rate of 22% among 50 patients, with a median response duration of 10.3 months. Among responders, 73% maintained response for at least six months. Safety evaluation in 376 patients showed serious adverse reactions in 33% of cases, with common side effects including fatigue, headache, and vomiting.
Modeyso represents the first treatment option for this ultra-rare and aggressive brain tumor, marking a significant advancement in patient care.
Jazz Pharmaceuticals (NASDAQ:JAZZ) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. Company management will conduct a fireside chat on September 3, 2025, at 6:30 a.m. PDT.
The presentation will be accessible through a live audio webcast on the company's investor relations website, with replays available for 30 days. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for sleep disorders, epilepsy, and cancer treatments.
Jazz Pharmaceuticals (NASDAQ: JAZZ) will host an investor webcast on August 27, 2025, at 4:30 p.m. EDT to discuss Modeyso™ (dordaviprone), their newly approved treatment for diffuse midline glioma. The presentation will feature insights from Jazz's senior management and Dr. Timothy Cloughesy, distinguished professor from UCLA Brain Tumor Center.
Notably, Modeyso received FDA accelerated approval on August 6, 2025, becoming the first and only approved treatment for patients aged 1 and older with H3 K27M-mutant diffuse midline glioma who have progressive disease after prior therapy. The webcast will cover clinical data, patient needs, and commercialization strategy for this breakthrough treatment.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has entered into a global licensing agreement with Saniona (Nasdaq OMX: SANION) for exclusive worldwide rights to develop and commercialize SAN2355, a preclinical asset for epilepsy treatment. Jazz will pay $42.5 million upfront to Saniona.
The agreement includes potential payments of up to $192.5 million in development and regulatory milestones, including $7.5 million for Phase 1 initiation, up to $800 million in commercial milestones, and tiered royalties from mid-single digits to low-double digits on net sales.
SAN2355 is a subtype-selective Kv7.2/Kv7.3 activator designed to overcome limitations of non-selective Kv7-targeting compounds. Jazz will lead and fund development, regulatory submissions, and global commercialization efforts.
Jazz Pharmaceuticals (NASDAQ: JAZZ) has achieved a groundbreaking milestone with the FDA's accelerated approval of Modeyso™ (dordaviprone), the first-ever treatment for H3 K27M-mutant diffuse midline glioma with progressive disease. This ultra-rare and aggressive brain tumor affects approximately 2,000 people annually in the U.S., primarily children and young adults.
The approval is based on clinical studies showing an overall response rate of 22% among 50 patients, with a median response duration of 10.3 months. Among responders, 73% maintained their response for at least six months. The safety evaluation, conducted across 376 patients, revealed serious adverse reactions in 33% of cases.
Modeyso, administered as a weekly oral capsule, will be commercially available in the coming weeks. Continued approval may depend on results from the Phase 3 ACTION confirmatory trial.
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 2025 financial results with total revenues of $1.05 billion, up 2% year-over-year. The company announced leadership transition with Renee Gala appointed as President and CEO effective August 11. Key product performance included Xywav revenue growth of 13% to $415.3 million with 625 new patients added. The company faced challenges with GAAP net loss of $718.5 million, largely due to a $905.4 million IPR&D expense from the Chimerix acquisition.
Notable pipeline developments include Zepzelca's Priority Review for first-line ES-SCLC treatment and Ziihera's European approval for HER2-positive biliary tract cancer. The company updated its 2025 guidance, projecting total revenue of $4.15-$4.30 billion, representing 4% growth at midpoint. Jazz also executed $125 million in share repurchases during Q2.
Jazz Pharmaceuticals (NASDAQ: JAZZ), a global biopharma company, has announced it will release its 2025 second quarter financial results on Tuesday, August 5, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss the results and provide business updates.
Participants are encouraged to register at least 15 minutes before the webcast through the company's website or direct registration link. A replay will be available in the Investors section of Jazz Pharmaceuticals' website. The company specializes in developing medicines for sleep disorders, epilepsy, and cancer treatments, with operations spanning multiple countries.
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that Renee Gala will become the company's new President and Chief Executive Officer, effective August 11, 2025. Gala, currently serving as President and COO, will succeed co-founder Bruce Cozadd, who will retire as CEO but continue as Board Chairperson.
Gala brings over 30 years of experience and has been instrumental in Jazz's transformation since joining as CFO in March 2020. Under her leadership as COO, the company achieved nearly 90% total revenue growth through portfolio diversification and strategic business development. The appointment follows a comprehensive succession planning process where the Board evaluated both internal and external candidates.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has received conditional marketing authorization from the European Commission for Ziihera® (zanidatamab) for treating adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC) who have received at least one prior line of systemic therapy.
The approval is based on the Phase 2b HERIZON-BTC-01 trial results, which demonstrated significant efficacy in the largest study conducted to date in this population. Key findings include:
- Confirmed objective response rate (cORR) of 41.3% in the overall population
- Higher cORR of 51.6% in IHC 3+ tumor patients
- Median duration of response of 14.9 months
- Median overall survival of 18.1 months in IHC 3+ patients
Ziihera becomes the first HER2-targeted therapy authorized for HER2-positive BTC in the European Union. The approval extends to all EU Member States, Iceland, Norway, and Liechtenstein. Continued approval is contingent upon verification of clinical benefit in the ongoing Phase 3 HERIZON-BTC-302 trial.